EML4 and non-small cell lung carcinoma: From the phosphopeptide analysis and cellular assays, we identified elevated expression of the ERBB3 and ERBB2 proteins after LOR treatment in EML4-ALK+positive NSCLC cells, we therefore investigated the effect of ligand-induced ERBB receptor activation in the context of TKI inhibition.